Corvus Pharmaceuticals, INC Form 4 insider transactions

Corvus Pharmaceuticals director David Scott Moore acquired 21,700 shares and received 15,000 stock options in a recent filing.

Corvus Pharmaceuticals director Ian T. Clark was granted 15,000 stock options as part of his compensation package.

Corvus Pharmaceuticals director Linda Grais was granted 15,000 stock options as part of standard equity compensation.

Corvus Pharmaceuticals director and 10% owner Peter A. Thompson was granted 15,000 stock options with an exercise price of $11.6.

Richard van den Broek, a Director at Corvus Pharmaceuticals, acquired 15,000 stock options on June 11, 2026, with an exercise price of $11.60.

Richard A. Miller, President and CEO of Corvus Pharmaceuticals, reported transactions involving the acquisition and disposition of company stock.

Director Andrew C. Chan was granted 30,000 stock options in Corvus Pharmaceuticals, Inc. as part of a standard equity incentive.

Peter A. Thompson, a Director and 10% owner of Corvus Pharmaceuticals, Inc., exercised multiple stock options to acquire 210,000 shares of common stock.

Corvus Pharmaceuticals, Inc. granted 400,000 stock options to William Benton Jones, SVP of Pharmaceutical Development, with an exercise price of $8.81 per share.

Corvus Pharmaceuticals' President and CEO, Richard A. Miller, MD, was granted 1,000,000 stock options with an exercise price of $8.81, vesting monthly over three years.

Corvus Pharmaceuticals' Chief Business Officer, Jeffrey Arcara, was granted 100,000 stock options with an exercise price of $8.81, vesting over three years.

Corvus Pharmaceuticals' Chief Financial Officer, Leiv Lea, was granted 400,000 stock options with an exercise price of $8.81, vesting monthly over three years.

Corvus Pharmaceuticals Director David Scott Moore was granted 30,000 stock options with an exercise price of $7.04, vesting over three years.

OrbiMed Private Investments V, LP, an affiliate of OrbiMed Advisors LLC, exercised common warrants to acquire 1,397,684 shares of Corvus Pharmaceuticals, Inc. common stock on a cashless basis.

An entity affiliated with Peter A. Thompson, a Director and 10% owner of Corvus Pharmaceuticals, exercised common warrants, resulting in a net increase of 221,352 shares in beneficial ownership.

Corvus Pharmaceuticals, Inc. Director Linda Grais was granted 15,000 stock options with an exercise price of $4.24, aligning her interests with shareholder value.

Corvus Pharmaceuticals, Inc. Director Ian T. Clark was granted 15,000 stock options with an exercise price of $4.24, vesting fully on the earlier of the first anniversary of the grant date or the 2026 Annual Meeting.

Corvus Pharmaceuticals, Inc. Director Scott W. Morrison was granted 15,000 stock options with an exercise price of $4.24, vesting over one year or by the 2026 Annual Meeting.

Corvus Pharmaceuticals, Inc. (CRVS) disclosed that Director and 10% Owner Peter A. Thompson was granted 15,000 stock options with an exercise price of $4.24, vesting over one year or by the 2026 Annual Meeting.

William Benton Jones, SVP of Pharmaceutical Development at Corvus Pharmaceuticals, Inc., has exercised warrants to acquire 19,357 shares of common stock, increasing his direct beneficial ownership.

Richard A. Miller, CEO of Corvus Pharmaceuticals, exercised warrants to acquire shares of common stock at $3.5 per share.

Director Richard van den Broek acquired 30,000 stock options in Corvus Pharmaceuticals on April 8, 2025, according to a Form 4 filing.

Jeffrey Arcara, Chief Business Officer of Corvus Pharmaceuticals, acquired 50,000 stock options on December 20, 2024, according to a Form 4 filing with the SEC.

William Benton Jones, SVP of Pharmaceutical Development at Corvus Pharmaceuticals, acquired stock options for 300,000 shares on December 20, 2024.

Corvus Pharmaceuticals' Chief Financial Officer, Leiv Lea, reported the acquisition of 300,000 stock options on December 20, 2024.

Richard A. Miller, CEO of Corvus Pharmaceuticals, was granted 750,000 stock options on December 20, 2024, according to a Form 4 filing with the SEC.

Director Linda Grais acquired 15,000 stock options in Corvus Pharmaceuticals on June 13, 2024.

Director Ian T. Clark reports acquisition of stock options in Corvus Pharmaceuticals.

Scott W. Morrison, a director of Corvus Pharmaceuticals, reported the acquisition of stock options in a recent SEC filing.

Director Terry P. Gould reports acquisition of stock options in Corvus Pharmaceuticals, indirectly held through Adams Street Partners.